GSK and CureVac announce strategic mRNA technology collaboration
For media and investors only
Issued: London UK; T?bingen, Germany/ Boston, MA, USA- Companies to collaborate on mRNA vaccine and monoclonal antibody research programmes in infectious diseases
- GSK to make equity investment of ?130m (?150m) in CureVac, and an upfront payment of ?104m (?120m)